My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Eli Lilly (NY:LLY)

1,016.33 -4.23 (-0.41%)

Streaming Delayed Price Updated: 11:17 AM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Neuropsychiatric Disorders and Treatment Market Projected to Show Strong Growth: Astrazeneca, AviadoBio, Astellas Pharma

December 07, 2023

Get an extensive Neuropsychiatric Disorders And Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Via SBWire

Topics Artificial Intelligence

Ozempic vs. Mounjaro:: Battle of the bulge

December 04, 2023

The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs, led by the popularity of Ozempic. Celebrity usage

Via MarketBeat

Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030

November 29, 2023

Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis.

Via SBWire

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

November 29, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

Eli Lilly and Company (NYSE: LLY) is a Leading Gainer in Thursday Morning Trading

November 02, 2023

Via Investor Brand Network

Eli Lilly and Company (NYSE: LLY) is a Stock Spotlight on 10/25

October 25, 2023

Via Investor Brand Network

Doing Your Holiday Shopping? These Stocks Might Make Great Gifts

December 04, 2023

No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet.

Via MarketBeat

Topics Bonds

These are the top sectors for blue chip growth in 2024

November 29, 2023

The sector results will be mixed in 2024 but the Health Care, Communications and Technology sectors (and some of their stocks) will post robust gains.

Via MarketBeat

Topics Economy Intellectual Property

Eli Lilly and Company (NYSE: LLY) is a Leading Gainer in Friday Morning Trading

October 06, 2023

Via Investor Brand Network

Eli Lilly and Company (NYSE: LLY) is a Stock Spotlight on 10/5

October 05, 2023

Via Investor Brand Network

Increase Prevalence of Diabetic Patients Driving Market Growth Projected to Reach $55 Billion by 2029

November 17, 2023

EQNX::TICKER_START (OTCPK:CNER),(NASDAQ:PODD),(NASDAQ:TNDM),(NYSE:LLY),(NYSE:ABT) EQNX::TICKER_END

Via FinancialNewsMedia

Type 1 Diabetes Market Comprehensive Study Explores Huge Growth by Key Players DiaVacs, XOMA Corp., Biodel, Macrogenics

November 14, 2023

Type 1 Diabetes Market Growth

Via SBWire

MarketBeat Week in Review – 11/6 - 11/10

November 11, 2023

Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week

Via MarketBeat

Topics Artificial Intelligence Economy

Will Eli Lilly's Zepbound be the next big weight-loss drug?

November 10, 2023

Eli Lilly got regulators' OK for weight-loss drug Zepbound, which will compete with Novo Nordisk's Wegovy. Analysts see Zepbound sales as high as $37 billion

Via MarketBeat

Investor patience tested as pharmaceutical stocks take a tumble

November 01, 2023

The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector

Via MarketBeat

J&J stock down as business unit mulls talc-related bankruptcy

October 31, 2023

Johnson & Johnson stock fell in the past week as talc-related lawsuits weigh on a subsidiary, which is mulling bankruptcy to mitigate payouts and settlements.

Via MarketBeat

Topics Bankruptcy Lawsuit

Zenith Epigenetics Ltd. Announces Collaboration with Cencora on ZEN-3694

October 25, 2023

Calgary, Alberta--(Newsfile Corp. - October 25, 2023) - Zenith Epigenetics Ltd. ("Zenith" or the "Company"), a global leader in epigenetics,...

Via Newsfile

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

October 23, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END

Via FinancialNewsMedia

Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing

October 23, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

Is the Ozempic-Driven DexCom Selloff Overdone?

October 18, 2023

Has glucose monitor maker DexCom corrected too much on fears of lost sales due to weight loss and diabetes drugs made by Novo Nordisk and Eli Lilly?

Via MarketBeat

Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race

October 17, 2023

Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to...

Via PressReach

Bristol Myers Squibb Joins Big Pharma’s Race to Dominate Oncology

October 17, 2023

Leading pharmaceutical companies are diving headfirst into oncology, sparking a buzz in the cancer treatment world. Bristol Myers Squibb is the latest company to join the movement, announcing its plan...

Via PressReach

Eli Lilly and Company (NYSE: LLY) Sets New 52-Week High in Friday Session

October 13, 2023

Via Investor Brand Network

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

October 13, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END

Via FinancialNewsMedia

Will Higher Ozempic Use Mean Slimmed-Down Food Sales?

October 12, 2023

Novo Nordisk's Ozempic, a weight loss drug, is making waves in the food industry, raising concerns about its effect on sales of calorie-laden products.

Via MarketBeat

Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race

October 10, 2023

Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant...

Via PressReach

Big Pharma’s Billion-Dollar Bets on Advanced Cancer Therapies

October 10, 2023

Big Pharma is continuing its oncology buying spree, with a flurry of multi-billion-dollar deals, partnerships, and investments creating a buzz in the cancer treatment space. American pharmaceutical...

Via PressReach

Elsevier Launches New Pharmapendium, Empowering Pharma Companies to Bring Novel Drugs to Market Faster and Increase Success of Regulatory Submissions

October 10, 2023

London, United Kingdom--(Newsfile Corp. - October 10, 2023) - Elsevier, a global leader in information and data analytics, has launched...

Via Newsfile

Topics Animal Testing

Eli Lilly, McKesson, Novartis Flash Promising Chart Action

October 09, 2023

Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities.

Via MarketBeat

Obesity Drug Boom, Split Make This Stock a Heavy Bargain

October 09, 2023

Ozempic users may be losing their appetites for sweets…but Novo Nordisk is one Danish treat that the market may only get hungrier for.

Via MarketBeat

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.